To establish the bioequivalence of two drug product batches of dabigatran etexilate, one batch containing only polymorph I vs. the other batch containing 17% of dabigatran etexilate polymorph II in addition to polymorph I
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
66
Area under the concentration-time curve of total BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 72 hours after drug administration
Maximum measured concentration of total BIBR 953 ZW in plasma (Cmax)
Time frame: Up to 72 hours after drug administration
Area under the concentration-time curve of free BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 72 hours after drug administration
Maximum measured concentration of free BIBR 953 ZW in plasma (Cmax)
Time frame: Up to 72 hours after drug administration
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)
Time frame: Up to 72 hours after drug administration
Area under the concentration time curve of the analyte in plasma over the time interval t1 to t2 (AUCt1-t2)
Time frame: t1 = 0 and t2 = 24, 48, 72 hours after drug administration
Time from dosing to the maximum concentration of the analyte in plasma (tmax)
Time frame: Up to 72 hours after drug administration
Terminal rate constant in plasma (λz)
Time frame: Up to 72 hours after drug administration
Terminal half-life of the analyte in plasma (t1/2)
Time frame: Up to 72 hours after drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mean residence time of the analyte in the body after oral administration (MRTpo)
Time frame: Up to 72 hours after drug administration
Apparent clearance of the analyte in the plasma after extravascular administration (CL/F )
Time frame: Up to 72 hours after drug administration
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)
Time frame: Up to 72 hours after drug administration
Change from baseline in physical examination
Time frame: Baseline, day 73
Change from baseline in vital signs (blood pressure, pulse rate)
Time frame: Baseline, day 73
Change from baseline in 12-lead ECG (electrocardiogram)
Time frame: Baseline, day 73
Change from baseline in clinical laboratory tests
Time frame: Baseline, day 73
Number of Participants with Serious and Non-Serious Adverse Events
Time frame: Up to day 73
Assessment of tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)
Time frame: Day 73